G protein–coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus

Research output: Contribution to journalReview ArticleResearchpeer-review

Abstract

G protein–coupled receptors (GPCRs) continue to be important discovery targets for the treatment of type 2 diabetes mellitus (T2DM). Many GPCRs are directly involved in the development of insulin resistance and b-cell dysfunction, and in the etiology of inflammation that can lead to obesity induced T2DM. This review summarizes the current literature describing a number of well-validated GPCR targets, but also outlines several new and promising targets for drug discovery. Wehighlight the importance of understanding the role of these receptors in the disease pathology, and their basic pharmacology, which will pave the way to the development of novel pharmacological probes that will enable these targets to fulfill their promise for the treatment of these metabolic disorders.

Original languageEnglish
Pages (from-to)39-67
Number of pages29
JournalPharmacological Reviews
Volume70
Issue number1
DOIs
Publication statusPublished - 1 Jan 2018

Cite this

@article{5d83495cfad0485da9f6c63654c65b9e,
title = "G protein–coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus",
abstract = "G protein–coupled receptors (GPCRs) continue to be important discovery targets for the treatment of type 2 diabetes mellitus (T2DM). Many GPCRs are directly involved in the development of insulin resistance and b-cell dysfunction, and in the etiology of inflammation that can lead to obesity induced T2DM. This review summarizes the current literature describing a number of well-validated GPCR targets, but also outlines several new and promising targets for drug discovery. Wehighlight the importance of understanding the role of these receptors in the disease pathology, and their basic pharmacology, which will pave the way to the development of novel pharmacological probes that will enable these targets to fulfill their promise for the treatment of these metabolic disorders.",
author = "Riddy, {Darren M.} and Philippe Delerive and Summers, {Roger J.} and Patrick Sexton and Langmead, {Christopher J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1124/pr.117.014373",
language = "English",
volume = "70",
pages = "39--67",
journal = "Pharmacological Reviews",
issn = "1521-0081",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

G protein–coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus. / Riddy, Darren M.; Delerive, Philippe; Summers, Roger J.; Sexton, Patrick; Langmead, Christopher J.

In: Pharmacological Reviews, Vol. 70, No. 1, 01.01.2018, p. 39-67.

Research output: Contribution to journalReview ArticleResearchpeer-review

TY - JOUR

T1 - G protein–coupled receptors targeting insulin resistance, obesity, and type 2 diabetes mellitus

AU - Riddy, Darren M.

AU - Delerive, Philippe

AU - Summers, Roger J.

AU - Sexton, Patrick

AU - Langmead, Christopher J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - G protein–coupled receptors (GPCRs) continue to be important discovery targets for the treatment of type 2 diabetes mellitus (T2DM). Many GPCRs are directly involved in the development of insulin resistance and b-cell dysfunction, and in the etiology of inflammation that can lead to obesity induced T2DM. This review summarizes the current literature describing a number of well-validated GPCR targets, but also outlines several new and promising targets for drug discovery. Wehighlight the importance of understanding the role of these receptors in the disease pathology, and their basic pharmacology, which will pave the way to the development of novel pharmacological probes that will enable these targets to fulfill their promise for the treatment of these metabolic disorders.

AB - G protein–coupled receptors (GPCRs) continue to be important discovery targets for the treatment of type 2 diabetes mellitus (T2DM). Many GPCRs are directly involved in the development of insulin resistance and b-cell dysfunction, and in the etiology of inflammation that can lead to obesity induced T2DM. This review summarizes the current literature describing a number of well-validated GPCR targets, but also outlines several new and promising targets for drug discovery. Wehighlight the importance of understanding the role of these receptors in the disease pathology, and their basic pharmacology, which will pave the way to the development of novel pharmacological probes that will enable these targets to fulfill their promise for the treatment of these metabolic disorders.

UR - http://www.scopus.com/inward/record.url?scp=85040020831&partnerID=8YFLogxK

U2 - 10.1124/pr.117.014373

DO - 10.1124/pr.117.014373

M3 - Review Article

VL - 70

SP - 39

EP - 67

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 1521-0081

IS - 1

ER -